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L E T T E R  T O  T H E  E D I T O R
Inaccurate conclusions by Tang and colleagues
I read with interest the study by Tang and colleagues, published 
March 27, 2020, entitled “Anticoagulant treatment is associated with 
decreased mortality in severe coronavirus disease patients with co-
agulopathy.” Unfortunately, this retrospective study came to conclu-
sions that are inaccurate with the information provided.
The authors use of the word “therapy” implies that patients were 
given therapeutic doses of anticoagulants; however, doses appear to 
be most consistent with prophylaxis dosing. The authors report that 
94 patients received enoxaparin at 40 to 60 mg/day. They did not 
specify the route of administration, subcutaneous or intravenous, 
nor did they specify the percentage of patients that received which 
dose. The 40 mg/day dose of enoxaparin given subcutaneous is the 
prophylactic dose. The 60 mg/day intravenous dose would be ther-
apeutic for patients weighing 40 kg, which is not a typical weight for 
an adult patient.
Review of the aforementioned suggests that the authors are re-
ally presenting data demonstrating that hospitalized COVID-19 pa-
tients should be on venous thromboembolism (VTE) prophylaxis, a 
position that should be unanimously supported as standard of care 
based on prior research that suggests that 11% of patients would de-
velop VTE.1 This has recently been reaffirmed by The International 
Society of Thrombosis and Haemostasis in their March 25, 2020, 
guidelines.2
There is concern that patients with COVID-19 are at higher risk of 
developing VTE. I am aware of just one study to date that attempted 
to elucidate the prevalence of VTE.3 This retrospective study reported 
that 25% of 81 patients with COVID-19 had a deep vein thrombosis 
(DVT). It is important to note that none of the 81 patients received 
VTE chemical prophylaxis and the authors of that study did not men-
tion whether patients received mechanical prophylaxis either. At my 
institution, we have diagnosed several critically ill COVID-19 patients 
with acute lower extremity DVTs with point-of-care ultrasonography. 
These patients developed DVTs despite chemical VTE prophylaxis.
The American Society of Hematology recommends against em-
piric therapeutic anticoagulation for COVID-19 patients given lack 
of evidence of benefit and potential harm.4 As the world fights this 
pandemic, high-quality prospective studies are required to further 
elucidate the best way to manage the coagulopathy that we are 
seeing in patients critically ill with COVID-19. Hospitals will need 
to establish safe ways to aggressively test for the presence of VTE 
in these patients to inform therapeutic anticoagulation, focusing on 
minimizing exposure of health care workers to the virus.
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